Company Profile

Bacilligen Inc
Profile last edited on: 2/20/08      CAGE: 4GAJ8      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2006
First Award
2007
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9700 Great Seneca Highway
Rockville, MD 20850
   (301) 217-9525
   info@bacilligen.com
   www.bacilligen.com
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Bacilligen is a biotechnology company focusing on the development of cancer and infectious disease vaccines and therapeutics. Bacilligen’s lead product is an improved bladder cancer therapy based on rMB, propriety recombinant mycobacteria. Bacilligen’s other product candidates, which include vaccines for AIDS, cancer, and influenza, are based on a novel bacteriophage capsid system, BVS, for the delivery of nucleic acid therapies and vaccines for cancer and infectious disease. Bacilligen’s BVS possesses speed and efficiency/cost advantages that make it the system of choice for rapid development and production of custom biological therapies and vaccines, including in personalized medicine and emergency preparedness set

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $253,882
Project Title: Improved Bladder Cancer Therapy With Recombinant BCG

Key People / Management

  Steve Bende -- President

  David M Hone

Company News

There are no news available.